What is the price target for BPTS stock?
8 analysts have analysed BPTS and the average price target is 0.38 USD. This implies a price decrease of -95.36% is expected in the next year compared to the current price of 8.22.
BIOPHYTIS SA-ADR (BPTS) Forecast, Price Target & Analyst Ratings
NASDAQ:BPTS • US09076G2030
Current stock price
8.22 USD
-1.48 (-15.28%)
At close:
7.92 USD
-0.3 (-3.65%)
After Hours:
Analyst forecast overview
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for BIOPHYTIS SA-ADR (BPTS).
Forecast Snapshot
Price Target Details & History
Consensus Price Target and Range
Mean target
$0.38
Upside
-95.36%
From current price of $8.22 to mean target of $0.38, Based on 8 analyst forecasts
Low
$0.36
Median
$0.38
High
$0.41
Price Target Revisions
1 Month
-21.70%
3 Months
-39.71%
Price Target Summary
8 Wall Street analysts provided a forecast for the next 12 months for BPTS. The average price target is 0.38 USD. This implies a price decrease of -95.36% is expected in the next year compared to the current price of 8.22.
The average price target has been revised downward by 39.71% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
37.50%
BPTS was analyzed by 8 analysts. The buy percentage consensus is at 38. So analysts seem to be rather negative about BPTS.
In the previous month the buy percentage consensus was at a similar level.
BPTS was analyzed by 8 analysts. More opinions would make the average more meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2023-08-16 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-08-08 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-02-27 | HC Wainwright & Co. | Reiterate | Buy |
| 2023-02-03 | HC Wainwright & Co. | Reiterate | Buy |
| 2021-10-25 | HC Wainwright & Co. | Initiate | Buy |
Next Earnings Forecast Details
Next Earnings Details
- Release Date
- Sep 25, 2024
Next Earnings Revisions
Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
N/A
EPS (3 Months)
N/A
Next Earnings Summary
Full Analyst Estimates 2024 - 2026
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | N/A | N/A -100.00% | N/A | ||||||||||
| EBITDA YoY % growth | -4.978M | -7.775M -56.19% | -9.704M -24.81% | -13.634M -40.50% | -15.42M -13.10% | -13.662M 11.40% | -26.504M -94.00% | -22.788M 14.02% | -13.53M 40.63% | N/A 50.52% | N/A -107.69% | N/A 55.56% | |
| EBIT YoY % growth | -5.043M | -7.942M -57.49% | -9.908M -24.75% | -13.861M -39.90% | -15.682M -13.14% | -13.942M 11.10% | -26.815M -92.33% | -23.272M 13.21% | -14.333M 38.41% | N/A 53.29% | N/A -115.38% | N/A 57.14% | |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | N/A | N/A | N/A | N/A 7.61% | N/A -34.12% | N/A 80.70% | N/A 179.60% | N/A -134.26% | N/A 75.00% | N/A -133.33% | N/A 57.14% | N/A |
All data in EUR
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| EPS Q2Q % growth |
|---|
| Revenue Q2Q % growth |
| EBITDA Q2Q % growth |
| EBIT Q2Q % growth |
All data in EUR
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
N/A
EPS Next 5 Year
N/A
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
N/A
Revenue Next 5 Year
N/A
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
15.87%
EBIT Next 5 Year
N/A
BIOPHYTIS SA-ADR / BPTS Forecast FAQ
Can you provide the upcoming earnings date for BIOPHYTIS SA-ADR?
BIOPHYTIS SA-ADR (BPTS) will report earnings on 2024-09-25.
What is the consensus rating for BIOPHYTIS SA-ADR (BPTS) stock?
The consensus rating for BIOPHYTIS SA-ADR (BPTS) is 37.5 / 100 . This indicates that analysts generally have a negative outlook on the stock.